Allergan plc (AGN)

140.31
0.28 0.20
NYSE
Prev Close 140.03
Open 140.16
Day Low/High 136.77 / 141.29
52 Wk Low/High 125.84 / 197.00
Volume 2.11M
Exchange NYSE
Shares Outstanding 330.22B
Market Cap 46.24B
Div & Yield N.A. (N.A)

Latest News

Jim Cramer: AAPL Should Get Into Diabetes Treatment and KHC Should Invest in Pot

Jim Cramer: AAPL Should Get Into Diabetes Treatment and KHC Should Invest in Pot

In this day and age, companies must be 'disruptors' or get left in the dust.

Watching Shares of Och-Ziff Capital Management

Watching Shares of Och-Ziff Capital Management

With shares breaking above the recent, albeit small, pennant, there might be reason for optimism.

Activists Aim to Eliminate Dual Role for Allergan CEO Saunders

Activists Aim to Eliminate Dual Role for Allergan CEO Saunders

David Tepper's Appaloosa LP renews calls for changes at the top.

Jim Cramer: No Room for Cynicism, JNJ's New Depression Drug Is Lifesaving

Jim Cramer: No Room for Cynicism, JNJ's New Depression Drug Is Lifesaving

The approval of esketamine, known as Spravato, for use against severe depression is special -- it is saving lives.

I Like These 2 Smaller Name Biotech Stocks

I Like These 2 Smaller Name Biotech Stocks

I still believe it will be a big year for buyouts across the biotech industry.

Evolus Stockholders May Be Frowning in the Short Run

Evolus Stockholders May Be Frowning in the Short Run

Shares of the Botox competitor could correct/consolidate after a recent surge.

How Are My Ideas Working Out? January Trade Review (Part 2)

How Are My Ideas Working Out? January Trade Review (Part 2)

Clearly, the first half of the month shaped up better than the second half.

Sloppy Earnings, China's Economy, AMD Earnings Preview: Market Recon

Sloppy Earnings, China's Economy, AMD Earnings Preview: Market Recon

What we have seen of late from a number of chip producers really might be interpreted as pre-recessionary.

Allergan Could Retest Its December Low Before a Better Rally Attempt

Allergan Could Retest Its December Low Before a Better Rally Attempt

Allergan could move higher but some sort of retest of the December low seems in order in the short to intermediate term.

Jim Cramer: What Are We to Make of Today's Market Decline?

Jim Cramer: What Are We to Make of Today's Market Decline?

Is it a retest based on the damage the Fed has already done, the result of a breakdown in trade talks or a sign of a slowing global economy?

Jim Cramer: This Market Takes Its Cue From the Positive and Ignores the Negative

Jim Cramer: This Market Takes Its Cue From the Positive and Ignores the Negative

So far 2019 is proving to be a year where things have a habit of working out right.

Try This Allergan Two-Week Setup

Try This Allergan Two-Week Setup

The company is set to report earnings on Jan. 29, so traders have a couple of weeks to watch the action.

Allergan Must Prove Itself With Signs of More Aggressive Buying

Allergan Must Prove Itself With Signs of More Aggressive Buying

A three-year decline in the shares of the maker of Botox will take more than a two-week bounce to reverse.

Real Money Post Industrial Average Outperformed the Market in 2018

Real Money Post Industrial Average Outperformed the Market in 2018

The RMPIA index was up for the year, while the S&P 500, DJIA, Russell 2000 and Nasdaq all finished 2018 in the red.

The Charts of Allergan Look Very Bearish With New Lows Made Yesterday

The Charts of Allergan Look Very Bearish With New Lows Made Yesterday

When I looked at the charts this morning I found a stock that could still decline further.

Jim Cramer: My Take on These Companies Where Lawsuits Are Front and Center

Jim Cramer: My Take on These Companies Where Lawsuits Are Front and Center

These are currently situations where companies are facing serious lawsuits.

Allergan Needs to Rebase on the Charts - Don't Rush It

Allergan Needs to Rebase on the Charts - Don't Rush It

Let's check the charts and technical indicators for some guidance.

Jim Cramer: Even Safe-Haven Big-Cap Drug Stocks Are Now Broken

Jim Cramer: Even Safe-Haven Big-Cap Drug Stocks Are Now Broken

Once the safest stocks in the book, the big-cap drug companies are now toxic.

Staying Long Apple Into Tuesday's Product Launch: Market Recon

Staying Long Apple Into Tuesday's Product Launch: Market Recon

My target price and panic points have changed, and I am watching for a chance to add or shave some off, depending on which direction the stock takes.

Jim Cramer: These Are the Stocks to Buy on Canada Deal and the 4th Quarter

Jim Cramer: These Are the Stocks to Buy on Canada Deal and the 4th Quarter

Straying from these names could land you in quicksand as the 4th quarter begins.

A Bullish Options Play on Allergan

A Bullish Options Play on Allergan

Buyout rumors aside, AGN is a name I still find attractive.

Allergan Has Finally Made a Base Pattern Traders Can Approach From the Long Side

Allergan Has Finally Made a Base Pattern Traders Can Approach From the Long Side

Let's check out the charts again so see how far this advance might carry.

Jim Cramer: This Is a Rotation, Not a Recession

Jim Cramer: This Is a Rotation, Not a Recession

There's too much evidence of economic strength, so don't interpret these moves as a sign of a real slowdown.

Biotechs: Adding to Radius Health, Flexion

Biotechs: Adding to Radius Health, Flexion

This downward action in the small biotech sector tends to happen often in the 'dog days' of summer.

Netflix and Twitter Are Among 29 Stocks Ready to Change Direction

Netflix and Twitter Are Among 29 Stocks Ready to Change Direction

These names are showing technical characteristics of either bullish or bearish reversal patterns over the past week.

3 Best Chip Stocks to Own After AMD's Monster Earnings Beat: Market Recon

3 Best Chip Stocks to Own After AMD's Monster Earnings Beat: Market Recon

Micron Technology, Intel and Lam Research are good buys on this heat in semiconductors.